Jörg Gabert

Jörg Gabert

Auto-generated profile, based on publicly available information

Jörg Gabert

AP Diagnostics GmbH, Leipzig 04103, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
JLJi Luo
Ji Luo
JKJennifer Klett
Jennifer Klett
JGJörg Gabert
Jörg Gabert
TLThomas Lipp
Thomas Lipp
JKJulia Karbach
Julia Karbach
SMSanja Milkovska-Stamenova
Sanja Milkovska-Stamenova
There is an ongoing need for high-precision serological assays for the quantitation of anti-SARS-CoV-2 antibodies. Here, a trimeric SARS-CoV-2 spike (S) protein was used to develop an ELISA to quantify specific IgG antibodies present in serum, plasma, and dried blood spots (DBS) collected from infected patients or vaccine recipients. The quantitative S-ELISA was calibrated with international anti-SARS-CoV-2 immunoglobulin standards to provide test results in binding antibody units per mL (BAU/mL). The assay showed excellent linearity, precision, and accuracy. A sensitivity of 100% was shown for samples collected from 54 patients with confirmed SARS-CoV-2 infection more than 14 days after symptom onset or disease confirmation by RT-PCR and 58 vaccine recipients more than 14 days after vaccination. The assay specificity was 98.3%. Furthermore, antibody responses were measured in follow-up samples from vaccine recipients and infected patients. Most mRNA vaccine recipients had a similar response, with antibody generation starting 2–3 weeks after the first vaccination and maintaining positive for at least six months after a second vaccination. For most infected patients, the antibody titers increased during the second week after PCR confirmation. This S-ELISA can be used to quantify the seroprevalence of SARS-CoV-2 in the population exposed to the virus or vaccinated.

10 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
MSMandy Schwarze
Mandy Schwarze
JLJi Luo
Ji Luo
ABAlexandra Brakel
Alexandra Brakel
AKAndor Krizsan
Andor Krizsan
NLNicole Lakowa
Nicole Lakowa
RHRalf Hoffmann
Ralf Hoffmann
This study investigated the IgG and IgA antibody response against recombinant S1 and receptor binding domains (RBD) of the spike (S-) protein and the membrane (M-) protein using a set of 115 serum samples collected from patients infected with SARS-CoV-2 in Germany before April 2021 using protein and peptide ELISA. As S1- and RBD-proteins expressed in Escherichia coli provided poor sensitivities in ELISA, they were replaced by proteins expressed in HEK cells. The RBD-ELISA provided a sensitivity of 90.6% (N = 85) for samples collected from patients with confirmed SARS-CoV-2 infections more than 14 days after symptom onset or a positive PCR test. In population-based controls, the specificity was 97.9% (N = 94). In contrast, the sensitivities were only 41.2% and 72.6% for M- and N-proteins, respectively, while the specificities were 88.5% and 100%, respectively. Considering also 20 samples collected during the first two weeks of symptom onset or PCR confirmation, the sensitivity of RBD- and N-protein ELISA decreased to 82.6% and 72.6%, respectively. The combination of two data sets, i.e., N- and RBD-, N- and M-, or RBD- and M-proteins increased the sensitivity to 85.8%, 77.9%, and 87.8%, respectively. Peptide mapping mostly confirmed epitopes previously reported for S1- and M-proteins, but they were only recognized by a few samples already tested positive in the corresponding protein ELISA indicating that peptide-based assays will not improve the diagnostic sensitivity.

26 August 2025 in Molecular Immunology
Verified
Journal Article
Open access
JLJi Luo
Ji Luo
SMSanja Milkovska-Stamenova
Sanja Milkovska-Stamenova
JKJulia Karbach
Julia Karbach
EJElke Jäger
Elke Jäger
RHRalf Hoffmann
Ralf Hoffmann
JGJörg Gabert
Jörg Gabert
Early diagnosis of cancer offers the best chance for effective treatment. Serological tests for the detection of cancer testis antigens (CTA) could aid in cancer diagnosis, prognosis, and treatment evaluation. Since NY-ESO-1 induces a strong immune response in several cancer types, it is considered an attractive CTA for antibody assay development. The full-length NY-ESO-1 protein was recombinantly produced in Escherichia coli, purified, and used to develop an indirect enzyme-linked immunosorbent assay (ELISA) for the detection of NY-ESO-1 specific antibodies. This ELISA was optimized and validated using serum samples collected from 78 confirmed cancer patients and control sera from healthy donors (n = 20) and rheumatoid arthritis patients (n = 43). The optimized NY-ESO-1 ELISA provided a sensitivity of 96.2 % in cancer patients and a specificity of 100 % for non-cancer donors. A follow-up study of patients undergoing cancer treatment indicated that the antibody levels were responsive to therapy, becoming very low or negative after successful treatment and rising again before tumor metastasis recurrence was confirmed. Comparative peptide ELISA using overlapping peptides of the full NY-ESO-1 sequence did not improve the detection rate, but did reveal common epitopes. The NY-ESO-1 protein-based ELISA could be used to detect potential cancer patients and is useful for monitoring cancer therapy and tumor recurrence after treatment.